The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC).
 
Chigusa Morizane
Honoraria - Lilly; Nobelpharma; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Makoto Ueno
Research Funding - Baxalta; Ono Pharmaceutical
 
Takashi Sasaki
No Relationships to Disclose
 
Fumio Nagashima
Honoraria - Chugai Pharma; Mitsubishi Tanabe Pharma; Nestle health science; Sanofi; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo; Eisai; Lilly; MSD Oncology; Sanofi; Sumitomo Dainippon; Taiho Pharmaceutical
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Lilly; Novartis; OncoTherapy Science; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Eisai (Inst); Merck Serono (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Satoshi Shimizu
Honoraria - Nippon Kayaku; Novartis; Taiho Pharmaceutical
 
Nozomi Hayata
Employment - Eisai
 
Hiroki Ikezawa
Employment - Eisai
 
Takuya Suzuki
Employment - Eisai
 
Ryo Nakajima
Stock and Other Ownership Interests - Astellas Pharma; Chiome Bioscience
 
Corina E. Dutcus
Employment - Eisai
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Lilly Japan; NanoCarrier
Research Funding - AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Eisai; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical